U.S. markets open in 20 minutes
  • S&P Futures

    4,413.00
    -25.00 (-0.56%)
     
  • Dow Futures

    34,474.00
    -170.00 (-0.49%)
     
  • Nasdaq Futures

    15,187.00
    -116.50 (-0.76%)
     
  • Russell 2000 Futures

    2,239.00
    -16.20 (-0.72%)
     
  • Crude Oil

    73.02
    -0.28 (-0.38%)
     
  • Gold

    1,744.30
    -5.50 (-0.31%)
     
  • Silver

    22.58
    -0.06 (-0.25%)
     
  • EUR/USD

    1.1707
    -0.0040 (-0.34%)
     
  • 10-Yr Bond

    1.4270
    +0.0170 (+1.21%)
     
  • Vix

    20.36
    -0.51 (-2.44%)
     
  • GBP/USD

    1.3663
    -0.0058 (-0.42%)
     
  • USD/JPY

    110.5720
    +0.2710 (+0.25%)
     
  • BTC-USD

    41,066.33
    -2,444.52 (-5.62%)
     
  • CMC Crypto 200

    1,019.03
    -89.89 (-8.11%)
     
  • FTSE 100

    7,048.19
    -30.16 (-0.43%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Alpine Immune Sciences' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Alpine Immune Sciences Inc (NASDAQ: ALPN) has presented the preclinical data from its ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting.

  • ALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc counterparts, as well as an anti-BAFF antibody.

  • ALPN-303 exhibited favorable preliminary developability characteristics, including higher serum exposure, lower clinical doses, or longer dosing intervals compared to WT TACI-Fc therapeutics.

  • In a mouse model of lupus, ALPN-303 treatment significantly suppressed anti-double-stranded DNA antibody titers, inflammation in the kidneys (glomerulonephritis), and salivary glands (sialadenitis) while preserving renal function and improving survival.

  • ALPN-303 is a potential candidate for the treatment of multiple autoimmune and inflammatory diseases, focusing on B cell-related disorders.

  • The first-in-human study is expected to start in later 2021.

  • See the slide presentation here.

  • Related content: Benzinga's Full FDA Calendar.

  • Price Action: ALPN shares closed at $10.14 on Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.